ZELFUSOR 5 mg, hard capsule 30 capsules
Active ingredients: Rosuvastatin, Rosuvastatin calcium
Commercialized according to BDPMDispensing in France: Prescription only
Hard capsule30 capsulesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- ZELFUSOR 5 mg, gélule
- Pharmaceutical form
- gélule
- Route of administration
- orale
- Presentation description
- plaquette(s) OPA : polyamide orienté aluminium PVC-Aluminium de 30 gélule(s)
- Marketing authorisation holder
- SUN PHARMACEUTICAL INDUSTRIES EUROPE (PAYS BAS)
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 8 Feb 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
62065528CIP73024349CIP133400930243497Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ROSUVASTATINE CALCIQUEgélule | — | SA |
| ROSUVASTATINEgélule | 5 mg · une gélule | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.